Watch – Our five key takeaways from ESMO

FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss five narratives from this year’s recently concluded ESMO congress, including the impact of Enhertu’s success on the antibody drug conjugate (ADC) field, the future of KRAs inhibitors and whether disrupting pricing in the PD-(L)1 inhibitor market will materialise.

To read more ViewPoints articles, click here.

Reference Articles